Dr. Bauml on Next Steps for Immunotherapy in Head and Neck Cancer

Joshua Bauml, MD
Published: Tuesday, Jul 25, 2017



Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the next steps for immunotherapy in head and neck cancer.

The next steps for immunotherapy in this disease is moving it earlier in the course of treatment, says Bauml.

For example, neoadjuvant pembrolizumab (Keytruda) showed major pathologic responses after a single dose in patients with resectable tumors.
 


Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the next steps for immunotherapy in head and neck cancer.

The next steps for immunotherapy in this disease is moving it earlier in the course of treatment, says Bauml.

For example, neoadjuvant pembrolizumab (Keytruda) showed major pathologic responses after a single dose in patients with resectable tumors.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder CancersApr 28, 20182.0
Publication Bottom Border
Border Publication
x